Breast and ovarian cancer risk evaluation in families with a disease-causing mutation in BRCA1/2

被引:3
|
作者
Beristain E. [1 ]
Ibáñez B. [2 ]
Vergara I. [2 ]
Martínez-Bouzas C. [1 ]
Guerra I. [3 ]
Tejada M.I. [1 ]
机构
[1] Molecular Genetics Laboratory, Biochemistry Department, Hospital de Cruces, 48903 Barakaldo, Bizkaia, Plaza de Cruces s/n
[2] Basque Foundation for Health Innovation and Research (BIOEF), 48150 Sondika, Plaza de Asua s/n
[3] Anatomy and Pathology Department, Hospital de Txagorritxu, 01006 Vitoria-Gasteiz, Jose Atxotegi s/n
关键词
Breast cancer; Cumulative risk; Ovarian cancer; Penetrance;
D O I
10.1007/s12687-010-0014-0
中图分类号
学科分类号
摘要
Germline mutations in BRCA1 and BRCA2 confer high risks of breast and ovarian cancer, and their identification allows genetic testing of at-risk relatives. However, estimates of these risks illustrate controversies, depending on the published series. The penetrance, the earlier onset of the disease and the effect of mutations on the risk of developing breast and ovarian cancer were evaluated in 344 females belonging to 34 families from the Basque Country in Spain, in which BRCA1 or BRCA2 mutations were transmitted. Kaplan-Meier survival curves were used to derive cumulative probability curves for breast and ovarian cancer by mutation status, birth cohort and mutation position, and significance of the differences was assessed using the logrank test. The estimated probability for breast cancer by age 70 is about 64% in BRCA1 and 69% in BRCA2, whereas the probability of developing ovarian cancer is about 37% and 25% for BRCA1 and BRCA2, respectively. There is a marginally significant higher risk of developing ovarian cancer in BRCA1 families than in BRCA2 families. The effect of birth cohort on breast cancer cumulative incidence presents an increased risk for females born after 1966 and a decreased risk for those born before 1940. There is no association between mutation position and breast cancer; however, ovarian cancer is associated to BRCA1, presenting exon 11 as an ovarian cluster. These results are important for the breast and ovarian cancer diagnosis and prevention in atrisk families. © Springer-Verlag 2010.
引用
收藏
页码:91 / 99
页数:8
相关论文
共 50 条
  • [11] Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic
    Martin, AM
    Blackwood, MA
    Antin-Ozerkis, D
    Shih, HA
    Calzone, K
    Colligon, TA
    Seal, S
    Collins, N
    Stratton, MR
    Weber, BL
    Nathanson, KL
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (08) : 2247 - 2253
  • [12] Indications for BRCA1 and BRCA2 mutation testing in hereditary breast and ovarian cancer families.
    Schmutzler, R
    Schwarz-Boeger, U
    Bastert, G
    Deininger, J
    Hahn, W
    Kast, K
    Prieshof, B
    Volm, T
    Kiechle, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 889S - 889S
  • [13] Germline mutation analysis of BRCA1 and BRCA2 genes in Yugoslav breast/ovarian cancer families
    Papp, J
    Raicevic, L
    Milasin, J
    Dimitrijevic, B
    Radulovic, S
    Olah, E
    ONCOLOGY REPORTS, 1999, 6 (06) : 1435 - 1438
  • [14] BRCA1 and BRCA2 germline mutation spectrum and frequencies in Belgian breast/ovarian cancer families
    Claes, K
    Poppe, B
    Coene, I
    De Paepe, A
    Messiaen, L
    BRITISH JOURNAL OF CANCER, 2004, 90 (06) : 1244 - 1251
  • [15] BRCA1 and BRCA2 germline mutation spectrum and frequencies in Belgian breast/ovarian cancer families
    K Claes
    B Poppe
    I Coene
    A De Paepe
    L Messiaen
    British Journal of Cancer, 2004, 90 : 1244 - 1251
  • [16] BRCA1 mutation analysis in 27 cypriot families with high risk of hereditary breast and ovarian cancer
    Hadjisavvas, A
    Adamou, A
    Kyriacou, KC
    Christodoulou, C
    DISEASE MARKERS, 1999, 15 (1-3) : 98 - 98
  • [17] Breast and Ovarian Cancer Risk and Risk Reduction in Jewish BRCA1/2 Mutation Carriers
    Finkelman, Brian S.
    Rubinstein, Wendy S.
    Friedman, Sue
    Friebel, Tara M.
    Dubitsky, Shera
    Schonberger, Niecee Singer
    Shoretz, Rochelle
    Singer, Christian F.
    Blum, Joanne L.
    Tung, Nadine
    Olopade, Olufunmilayo I.
    Weitzel, Jeffrey N.
    Lynch, Henry T.
    Snyder, Carrie
    Garber, Judy E.
    Schildkraut, Joellen
    Daly, Mary B.
    Isaacs, Claudine
    Pichert, Gabrielle
    Neuhausen, Susan L.
    Couch, Fergus J.
    van't Veer, Laura
    Eeles, Rosalind
    Bancroft, Elizabeth
    Evans, D. Gareth
    Ganz, Patricia A.
    Tomlinson, Gail E.
    Narod, Steven A.
    Matloff, Ellen
    Domchek, Susan
    Rebbeck, Timothy R.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (12) : 1321 - 1328
  • [18] IMPACT OF PREGNANCY ON THE RISK OF BREAST AND OVARIAN CANCER IN BRCA1 AND BRCA2 MUTATION CARRIERS
    Russo, M.
    Corvetto, E.
    Fais, M.
    Candotti, G.
    Locati, V.
    Proto, A.
    Angioni, S.
    Carcassi, C.
    Mais, V.
    Peiretti, M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A391 - A391
  • [19] Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families
    de Bock, G.
    van der Kolk, D.
    Schaapveld, M.
    Jansen, L.
    Mourits, M. J.
    Oosterwijk, J. C.
    EJC SUPPLEMENTS, 2010, 8 (03): : 224 - 224
  • [20] BRCA1 and BRCA2 mutation screening in breast cancer families.
    Phelan, CM
    Lancaster, JM
    Gumbs, C
    de los Rios, P
    Abrahamson, J
    Warner, E
    Parfrey, NA
    Futreal, PA
    Narod, SA
    BRITISH JOURNAL OF CANCER, 1998, 78 : 12 - 12